JUL 1 8 2014

510(k) Summary

5.1 Type of Submission: Traditional

5.2 Preparation Date: 20th January 2014

5.3 Submitter:

Address:	NeuroInvent Inc. 211 Hope Street, Ste 390082 Mountain View, CA 94039, U.S.A.
Phone:	+001-917-915-3568
Fax:	+001-650-353-9398
Contact:	Chao-Shent Chao (kuo-tai-hospitals@hotmail.com)

5.4 Identification of the Device:

Trade name:	E-Shield Multi-paired Subdermal Needle Electrodes
Classification Name:	Needle Electrode
Device Classification:	II
Regulation Number:	882.1350
Panel:	Neurology
Product Code:	GXZ

5.5 Identification of the Predicate Device:

Predicate Device Name:	Rhythmlink International Subdermal Needle Electrodes
Manufacturer:	Rhythmlink International, LLC
Product Code:	GXZ
510(k) Number:	K022914

5.6 Intended Use

E-Shield Multi-paired Subdermal Needle Electrodes are intended for use with recording and monitoring equipment for the purpose of recording of biopotential signals. Examples include: Electromyography (EMG), Electroencephagraph (EEG) and Nerve potential signals. The electrodes are sterile and for single patient use only.

5.7 Device Description

E-Shield Multi-paired Subdermal Needle Electrodes are single use, disposable, monopolar, non-pyrogenic and sterilized stainless steel subdermal needle electrodes. Electrodes are applied in the study of biopotentials such as electroencephalograph (EEG), electromyography (EMG). Electrodes are invasive as they are placed subcutaneously or in contact with nerve or muscle tissue.

The subdermal needle electrodes can be used to record variety of types of neurological and neurophysiological evoked potentials, including but not limited to electroencephalogram (EEG), electromyogram (EMG) in hospital and clinical setting. It is highly recommended to be used of intra-operative neuromonitoring (IOM).

The electrodes consist of a stainless steel needle with a lead wire attached and the lead wires terminate in a safety connector. The electrodes are used under the supervision of a physician. Each sterilized PET box contains 2 sets of 5-paired subdermal needle electrodes and a safety shield attached to each set. The safety shield is used to cover the needle sharps and the multi-paired lead wires are designed in group for easy organizing. Grouped wire cable can be separated into 5 paired lead wires to reach different recording sites of a patient over desired length. For instance, it can be used for the recording in one limb muscle groups.

5.8 Non-clinical Testing

A series of safety tests were performed to assess the safety and effectiveness of the E-Shield Multi-paired Subdermal Needle Electrodes.

Testing Item	Standard and regulations applied
Biocompatibility	ISO 10993-5:2009 Biological evaluation of medical devices - Part 5: Tests for *in vitro* cytotoxicity
	ISO 10993-10:2010 Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization
	ISO 10993-11:2009 Biological evaluation of medical devices - Part 11: Tests for systemic toxicity
	ISO 10993-12:2012 Biological evaluation of medical devices - Part 12: Sample preparation and reference material
	ASTM F756-08, Standard Practice For Assessment Of Hemolytic Properties Of Materials.(Biocompatibility)
	USP 35-NF30:2012, <151> Pyrogen Test (USP Rabbit Test).(Sterility)
	ASTM F750-87 (Reapproved 2012), Standard Practice For Evaluating Material Extracts By Systemic Injection In The Mouse. (Biocompatibility)
Sterilization	ISO 10993-7:2008 Biological evaluation of medical device -Part 7: Ethylene Oxide sterilization residuals
	ISO 11135-1 2007 Sterilization of health care products - Ethylene oxide – Requirements for development, validation and routine control of a sterilization process for medical devices
	ISO 11135-2 2008 Sterilization of health care products - Ethylene oxide –Guidance on the application of ISO 11135-1
	ISO 11737-1: 2006 Sterilization of Medical Devices – Microbiological Method – Part 1: Determination of a population of microorganisms on products
	ISO 11737-2: 2009 Sterilization of medical devices – Microbiological methods – Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process
Shelf life	ASTM F1980-07 Standard Guide for Accelerated Aging of Sterile Medical Device Packages.

	ASTM F88/F88M-09 Standard Test Method for Seal Strength of Flexible Barrier Materials
	ASTM F1140-13 Standard Test Methods for Internal Pressurization Failure Resistance of Unrestrained Packages for Medical Applications.
	ASTM F1929-12 Standard Test Method for Detecting Seal Leaks in Porous Medical Packaging by Dye Penetration.
	ASTM D4332: 2001 Standard practice conditioning containers, packages or packaging components for testing.
	ASTM F1608 Standard Test Method for Microbial Ranking of Porous Packaging Materials (Exposure Chamber Method).
	ASTM D4169-09, Standard Practice For Performance Testing Of Shipping Containers And Systems. (Sterility)
	ISO 11607-1 Packaging For Terminally Sterilized Medical Devices - Part 1: Requirements For Materials, Sterile Barrier Systems And Packaging Systems. (Sterility)
	ISO 11607-2 Packaging For Terminally Sterilized Medical Devices - Part 2: Validation Requirements For Forming, Sealing And Assembly Processes. (Sterility)
	ASTM F2096-11, Standard Test Method For Detecting Gross Leaks In Packaging By Internal Pressurization (Bubble Test). (Sterility)
	The International Safe Transit Association (ISTA) Procedure 1A
Electromagnetic Compatibility & Electrical Safety	IEC 60601-1 Medical electrical equipment Part 1: General requirements for basic safety and essential performance
Performance	ISO 9626 First Edition 1991-09-01, Amendment 1 2001-06-01 Stainless Steel Needle Tubing For The Manufacture Of Medical Devices. (General Plastic Surgery/General Hospital)
	ASTM B193-87(1992): Standard Test Method for Resistivity of Electrical Conductor Materials

	IEC 60028 (1925): International standard of resistance for copper
	GB/T 3048.2-2007: TEST method for electrical properties of electric cables and wire-part2: Test of electrical resistivity of metallic materials

All the test results demonstrate E-Shield Multi-paired Subdermal Needle Electrodes meet the requirements of its pre-defined acceptance criteria and intended uses.

5.9 Clinical Testing

No clinical test data was used to support the decision of safety and effectiveness.

5.10 Substantial Equivalence Determination

E-Shield Multi-paired Subdermal Needle Electrodes has similar intended use, fundamental scientific technology and technological characteristics with the predicate device, Rhythmlink International Subdermal Needle Electrodes. Information described below can demonstrate the E-Shield Multi-paired Subdermal Needle Electrodes is substantial equivalent to the predicate device.

	Proposed Device	Predicate Device
Item	E-Shield Multi-paired Subdermal Needle Electrodes	Rhythmlink International Subdermal Needle Electrodes
Classification	II	II
Regulation No.	882.1350	882.1350
Product Code	GXZ	GXZ
Intended Use	E-Shield Multi-paired Subdermal Needle Electrodes are intended for use with recording and monitoring equipment for the purpose of recording of biopotential signals. Examples include: Electromyography (EMG),	Rhythmlink International Subdermal Needle Electrodes are intended for use with recording, monitoring and stimulation equipment for the purpose of recording of biopotential signals. Examples include:

	Electroencephagraph (EEG) and Nerve potential signals. The electrodes are sterile and for single patient use only.	Electromyography (EMG), Electroencephagraph (EEG) and Nerve potential signals. The electrodes are sterile and for single patient use only.
Design	Monopolar	Monopolar
Anatomical sites	Subdermal, nerve or muscle tissue	Subdermal, nerve or muscle tissue
Materials	Stainless steel needle with lead wire attached.	Stainless steel needle with lead wire attached
Sterility	EO	unknown
Shelf life	3 years	unknown
Mechanical safety	Packaged needle covered with a needle cover	unknown

5.11 Similarity and differences

The only difference between the subject device and predicate device is the proposed device is designed in 5-paired subdermal needle electrodes and a safety shield attached to each set. The safety shield is used to cover the needle sharps and the multi-paired lead wires are designed in group for easy organizing. Grouped wire cable can be separated into 5 paired lead wires to reach different recording sites of a patient over desired length. The subject device has tested on safety and performance tests and the test results were complied with the test requests. Therefore, the difference of subject device and predicate device didn't raise any problems of safety or effectiveness. The proposed device is substantially equivalent to the predicate device in design, operation, intended use and performance claims.

5.12 Conclusion

After analyzing bench tests and safety testing data, it can be concluded that E-Shield Multi-paired Subdermal Needle Electrodes is as safe and effective as the predicate device.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

July 18, 2014

Neuroinvent, Inc.
c/o Chao-Shent Chao
Kuo Tai Hospitals Management & Consultant Co. Ltd.
5F, No. 123 anMei St.
Neihu District, Taipei City, 11484
Taiwan

Re: K140200
Trade/Device Name: E-Shield Multi-paired Subdermal Needle Electrodes
Regulation Number: 21 CFR 882.1350
Regulation Name: Needle Electrode
Regulatory Class: II
Product Code: GXZ
Dated: June 16, 2014
Received: June 17, 2014

Dear Mr. Chao-Shent Chao:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Felipe Aguel -S

for Carlos L. Peña, Ph.D., M.S.
Director
Division of Neurological
and Physical Medicine Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below.

510(k) Number *(if known)*
K140200

Device Name
E-Shield Multi-paired Subdermal Needle Electrodes

Indications for Use *(Describe)*

E-Shield Multi-paired Subdermal Needle Electrodes are intended for use with recording and monitoring equipment for the purpose of recording of biopotential signals. Examples include: Electromyography (EMG), Electroencephagraph (EEG) and Nerve potential signals. The electrodes are sterile and for single patient use only.

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) *(Signature)*

Felipe Aguel -S Date: 2014.07.18 13:32:49 -04'00'

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."